Brain-Stimulation / ASPD-Symptom Audit — v0.3.7

Question under audit

Do Fanti's non-invasive brain-stimulation studies demonstrate both:

1. improved emotion recognition / emotional attention; and
2. a reduction in symptoms associated with antisocial personality disorder (APD/ASPD)?

The 2026 EFCAP keynote states that non-invasive brain stimulation may enhance emotion recognition, leading to a decrease in symptoms associated with antisocial personality disorder.

The 2026 EAPL keynote states that non-invasive brain stimulation produces improvements in emotion recognition and reductions in symptoms associated with antisocial personality disorder.

Primary keynote sources:

• https://cyprusconferences.org/efcap2026/keynote-speakers/
• https://eapl2026.com/keynote-lectures/

Anchor study — Konikkou, Kostantinou & Fanti (2020)

Citation: Konikkou K, Kostantinou N, Fanti KA. Transcranial magnetic stimulation over the dorsolateral prefrontal cortex affects emotional processing: accounting for individual differences in antisocial behavior. Journal of Experimental Criminology. 2020;16:349–366. DOI: 10.1007/s11292-020-09440-z.

Full text: https://nkonstantinou.com/publication/konikkou-jec-2020/Konikkou-JEC-2020.pdf

Population

• N = 93 young adults.
• Participants were medication-free and were screened to exclude psychiatric/neurological disorders.
• The authors explicitly state that the participants were healthy individuals without an APD diagnosis.

APD measurement

• APD symptoms were measured using the Adult Self-Report Inventory-4 (ASRI-4).
• The ASRI-4 provided a dimensional symptom-severity score; the paper explicitly states that the measure does not establish a clinical diagnosis.
• Participants were divided by a median split of pre-stimulation APD scores into:
  • High APD: N = 38, M = 3.06, SD = 1.35
  • Low APD: N = 55, M = 0.34, SD = 0.48
• High-APD participants also scored higher on anxiety, depression, and CU traits. Those variables were tested as covariates and were not significant covariates in the emotion-recognition model.

Intervention/manipulation

Single-session inhibitory cTBS:

• left DLPFC real cTBS;
• right DLPFC real cTBS;
• left sham;
• right sham.

The study used a sham-controlled, blinded design. cTBS lasted 40 seconds (600 pulses) at 70% active motor threshold.

Actual dependent variable

After stimulation participants completed a dynamic facial-emotion-recognition task involving:

• happiness;
• fear;
• pain;
• sadness.

The principal outcome was emotion-recognition accuracy/error, not APD symptom change.

Direct result

Real stimulation improved recognition of selected emotions relative to sham. The stimulation-by-emotion effects were concentrated in the high APD-symptom group:

• left DLPFC cTBS: better recognition of happy, painful, and sad expressions relative to relevant sham comparisons;
• right DLPFC cTBS: better recognition of happy expressions relative to sham.

The study therefore supports the proposition:

Acute DLPFC cTBS can alter facial-emotion-recognition performance, with stronger detectable effects among participants elevated on APD symptoms.

What was not tested

The study did not:

• remeasure APD symptoms after stimulation;
• test pre/post APD symptom change;
• test diagnosed ASPD patients;
• measure aggression reduction as a treatment outcome;
• test durable symptom change;
• provide follow-up;
• establish that improving emotion recognition mediates later antisocial-symptom reduction.

The paper itself acknowledges:

• no pre-stimulation baseline emotion-recognition task;
• healthy, non-APD-diagnosed sample;
• need for replication in clinically diagnosed APD;
• need for multi-session designs and long-term investigation;
• that some proposed neural mechanisms remain speculative.

The authors frame TMS as a potential clinical tool and explicitly call for future work combining multi-session stimulation, neuroimaging, and cognitive/attention interventions.

2025 study 1 — repeated cTBS + AMT

Sikki M, Konikkou K, Kostantinou N, Fanti KA. Testing the effectiveness of combined attention modification training with right dorso-lateral prefrontal cortex theta-burst stimulation on reducing levels of anxiety and attentional bias. Experimental Brain Research. 2025;243:137. DOI: 10.1007/s00221-025-07040-9.

Source: https://link.springer.com/article/10.1007/s00221-025-07040-9

Relevance to ASPD claim

This study extends the 2020 program from a single-session mechanism experiment to eight cTBS/AMT sessions over two weeks, but the selected treatment outcome was anxiety/attentional bias in young adults differentiated on anxiety severity.

It did not provide an APD/ASPD symptom-reduction endpoint.

The combined active condition was not superior to sham cTBS + active AMT for anxiety reduction, while positive-attention and gaze measures changed. This reinforces the distinction between:

neural/cognitive mechanism change

and

demonstrated psychiatric symptom reduction.

See Audit-EAPL-05-TMS-AMT-Anxiety.

2025 study 2 — DLPFC cTBS and emotional attention

Konikkou K, Isdahl-Troye A, Sikki M, Fanti K. Effects of Continuous Theta Burst Stimulation to the Dorsolateral Prefrontal Cortex on Attention to Emotional Stimuli: A Randomized Controlled Trial. Brain Sciences. 2025;15(12):1328. DOI: 10.3390/brainsci15121328.

Sources:

• https://www.mdpi.com/2076-3425/15/12/1328
• https://pubmed.ncbi.nlm.nih.gov/41440124/

Population and endpoint

• N = 91 healthy young adults.
• Random allocation to real/sham left/right DLPFC cTBS.
• Outcome: dot-probe attentional response to pleasant, distressing, and neutral stimuli.

Direct result

Real cTBS altered attentional performance for emotional versus neutral information. The paper concludes that DLPFC is a useful cognitive target for advancing cTBS protocol design.

Inference boundary

There was no APD/ASPD symptom endpoint and no antisocial clinical population. This is mechanism evidence, not symptom-efficacy evidence.

Integrated claim ladder

Proposition A — DLPFC stimulation alters emotional processing

Status: supported.

Evidence:

• 2020: facial-emotion recognition altered after cTBS.
• 2025: emotional attention altered after cTBS.
• 2025 cTBS+AMT: positive-attention/gaze changes after combined intervention.

Proposition B — the 2020 effect is relevant to elevated APD symptoms

Status: supported with qualification.

The 2020 stimulation effect was concentrated among participants above the sample median on an ASRI-4 APD symptom score. However:

• this was not a diagnostic ASPD sample;
• APD was a baseline grouping/moderating variable;
• the median split was sample-relative rather than a diagnostic threshold.

Proposition C — cTBS reduces APD/ASPD symptoms

Status: not demonstrated in the located Fanti-led evidence.

No located study in this branch measured APD/ASPD symptoms before and after stimulation and demonstrated a treatment-associated reduction.

Proposition D — improved emotion recognition leads to reduced APD/ASPD symptoms

Status: mechanistic/clinical hypothesis; causal bridge untested in the located evidence.

The 2020 experiment demonstrates an acute effect on an emotional-processing task. It does not demonstrate that this cognitive change subsequently causes antisocial-symptom reduction.

Audit judgment

Status: tension / matched-proximal

The strongest defensible formulation is:

Fanti and colleagues have experimental evidence that DLPFC cTBS can alter emotion recognition and emotional attention, including an acute emotion-recognition effect concentrated among young adults with elevated self-reported APD symptoms. In the located studies, however, APD/ASPD symptoms were not demonstrated to decrease as a treatment outcome.

The 2026 keynote wording therefore appears to compress a supported proximal mechanism finding and a more distal clinical treatment proposition into one sentence.

Possible explanations include:

• unpublished/newer symptom data;
• conference-level synthesis drawing partly on external TMS literature;
• inferential compression from emotion-processing improvement to expected antisocial-symptom improvement.

Until a results-bearing Fanti/DPL source directly demonstrates APD/ASPD symptom reduction, the atlas must keep those propositions separate.

Genealogy consequence

Replace:

brain stimulation → improved emotion recognition → reduced ASPD symptoms

with:

DLPFC cTBS → acute emotion-recognition change ■ → emotional-attention change ■ → effects moderated by elevated APD symptom level (2020) ■ → hypothesis that mechanism change may improve antisocial symptoms □ → direct APD/ASPD symptom reduction demonstrated OPEN

Confidence

• emotion-recognition effect: fulltext-verified
• APD symptom grouping/moderation: fulltext-verified
• clinical diagnosis: explicitly absent
• APD/ASPD symptom reduction: not located / not demonstrated